1H-MRS at 4 Tesla in minimally treated early schizophrenia

Bustillo, J R, Rowland, L M, Mullins, P, Jung, R, Chen, H, Qualls, C, Hammond, R, Brooks, W M +1 more·2010·Molecular Psychiatry
DOI 10.1038/mp.2009.121

Cited by (153)

Items 101–153 of 153

  1. T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia
    Bethany K. Bracken, Elizabeth D. Rouse, Perry Franklin Renshaw, David P. Olson · 2013 · Psychiatry Research Neuroimaging
  2. Neuroprotective Effect of Modified Electroconvulsive Therapy for Schizophrenia
    Jingli Gan, Hui-feng Duan, Zhengxiang Cheng, Jia-ming Yang, Xi-Quan Zhu, Gao Cun-you, Zhao Lan-min, Xuejun Liang · 2017 · The Journal of Nervous and Mental Disease
  3. Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex
    Lejia Fan, Liangbing Liang, Yujue Wang, Xiaoqian Ma, Yuan Liu, Lijun Ouyang, Ying Hé, Zongchang Li, Chunwang Li, Xiaogang Chen et al. · 2023 · Neuropsychopharmacology
  4. Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review
    Bradley J. Dixon, Jyothika Kumar, Claudia Danielmeier · 2021 · Neuroscience & Biobehavioral Reviews
  5. Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: A magnetic resonance spectroscopy study
    Jingli Gan, Zhengxiang Cheng, Hui-feng Duan, Jia-ming Yang, Xi-Quan Zhu, Gao Cun-you · 2014 · Psychiatry Research Neuroimaging
  6. Social isolation stress and chronic glutathione deficiency have a common effect on the glutamine‐to‐glutamate ratio and myo‐inositol concentration in the mouse frontal cortex
    Alberto Corcoba, Rolf Gruetter A, Kim Q., João M. N. Duarte · 2017 · Journal of Neurochemistry
  7. Progressive symptom-associated prefrontal volume loss occurs in first-episode schizophrenia but not in affective psychosis
    Toshiyuki Ohtani, Elisabetta C. del Re, James Jonathan Levitt, Margaret A. Niznikiewicz, Jun Sakakibara Konishi, Takeshi Asami, Toshiro Kawashima, Tomohide Roppongi, Paul G. Nestor, Martha Elizabeth Shenton et al. · 2018 · Brain Structure and Function
  8. N-acetylaspartate concentration in psychotic disorders: T2-relaxation effects
    Elliot Kuan, Xi Chen, Fei Du, Döst Öngür · 2021 · Schizophrenia Research
  9. Recent Updates on Predicting Conversion in Youth at Clinical High Risk for Psychosis
    Noe Caballero, Siddharth N. Machiraju, Anthony Diomino, Leda Kennedy, Armita Kadivar, Kristin S. Cadenhead · 2023 · Current Psychiatry Reports
  10. Diffuse Brain Abnormalities in Myotonic Dystrophy Type 1 Detected by 3.0 T Proton Magnetic Resonance Spectroscopy
    Yuhei Takado, Kenshi Terajima, Masaki Ohkubo, Kouichirou Okamoto, Takayoshi Shimohata, Masatoyo Nishizawa, Hironaka Igarashi, Tsutomu Nakada · 2015 · European Neurology
  11. The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A 1H-MRS study in first-episode psychosis patients
    Uzma Zahid, Robert Ali McCutcheon, Faith Borgan, Sameer Jauhar, Fiona Pepper, Matthew M. Nour, Maria Rogdaki, Martin Osugo, Graham K. Murray, Pamela Hathway et al. · 2022 · Frontiers in Psychiatry
  12. An integrative study of the microbiome gut-brain-axis and hippocampal inflammation in psychosis: Persistent effects from mode of birth
    Peter Joe, José C. Clemente, Enrica Piras, David S. Wallach, Jessica Robinson‐Papp, Emeka Boka, Brooke Remsen, Mharisi Bonner, David Kimhy, Deborah M. Goetz et al. · 2021 · Schizophrenia Research
  13. Dopamine Synthesis Capacity and GABA and Glutamate Levels Separate Antipsychotic-Naïve Patients With First-Episode Psychosis From Healthy Control Subjects in a Multimodal Prediction Model
    Anne Korning Sigvard, Kirsten Borup Bojesen, Karen S. Ambrosen, Mette Ødegaard Nielsen, ALBERT H. GJEDDE, Karen Tangmose, Yoshitaka Kumakura, Richard A.E. Edden, Dan Fuglø, Lars Thorbjørn Jensen et al. · 2022 · Biological Psychiatry Global Open Science
  14. Acute Restraint-Mediated Increases in Glutamate Levels in the Rat Brain: An In Vivo 1H-MRS Study at 4.7 T
    Sang-Young Kim, Eun-Ju Jang, Kwan Su Hong, Chulhyun Lee, Do‐Wan Lee, Chi‐Bong Choi, Hyun-Seung Lee, Bo‐Young Choe · 2011 · Neurochemical Research
  15. Neurodegenerative Aspects in Vulnerability to Schizophrenia Spectrum Disorders
    Trevor Archer, Serafino Ricci, Danilo Garcia, Max Rapp Ricciardi · 2014 · Neurotoxicity Research
  16. Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion
    Maria Rogdaki, Pamela Hathway, Maria Gudbrandsen, Robert Ali McCutcheon, Sameer Jauhar, Eileen Daly, Oliver David Howes · 2019 · European Neuropsychopharmacology
  17. Neurometabolic abnormalities in the associative striatum in antipsychotic-naïve first episode psychosis patients
    Soumya Sivaraman, Nina Vanessa Kraguljac, David Matthew White, Charity Johanna Morgan, Sara S. Gonzales, Adrienne Carol Lahti · 2018 · Psychiatry Research Neuroimaging
  18. The predictive value of baseline NAA/Cr for treatment response of first-episode schizophrenia: A 1H MRS study
    Weibo Liu, Hualiang Yu, Biao Jiang, Bing Pan, Shaohua Yu, Hui‐Chun Li, Leilei Zheng · 2015 · Neuroscience Letters
  19. The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study
    Vladimir Grošić, Petra Folnegović Grošić, Petra Kalember, Maja Bajs Janović, Mate Mihanović, Neven Henigsberg, Marko Radoš · 2014 · Neuropsychiatric Disease and Treatment
  20. Functional magnetic resonance imaging reveals abnormal brain connectivity in EGR3 gene transfected rat model of schizophrenia
    Tianbin Song, Binbin Nie, Ensen Ma, Jing Che, Shilong Sun, Yuli Wang, Baoci Shan, Yawu Liu, Senlin Luo, Guolin Ma et al. · 2015 · Biochemical and Biophysical Research Communications
  21. Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats
    Charalampos Brakatselos, Alexia Polissidis, George Ntoulas, Michail-Zois Asprogerakas, O. Tsarna, Anastasia Vamvaka-Iakovou, Gerasimos Nakas, Anastasios D. Delis, Petros Tzimas, Alexios‐Léandros Skaltsounis et al. · 2024 · Neuropsychopharmacology
  22. Developmental changes in cerebral NAD and neuroenergetics of an antioxidant compromised mouse model of schizophrenia
    R. Skupienski, Pascal Steullet, Kim Q., Lijing Xin · 2023 · Translational Psychiatry
  23. Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: An in vivo magnetic resonance spectroscopy study
    Diana M. Lindquist, Richard Scott Dunn, Kim M. Cecil · 2011 · Schizophrenia Research
  24. The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks
    Hanna Elin van den Munkhof, Jørn Arnt, Pau Celada, Francesc Artigas · 2017 · European Neuropsychopharmacology
  25. Glutamine and GABA alterations in cingulate cortex may underlie alcohol drinking in a rat model of co-occurring alcohol use disorder and schizophrenia: an 1H-MRS study
    Patrick McCunn, Xi Chen, Barjor Gimi, Alan I. Green, Jibran Younis Khokhar · 2022 · Schizophrenia
  26. Multivoxel Proton MR Spectroscopy Used to Distinguish Anterior Cingulate Metabolic Abnormalities in Patients with Schizophrenia
    Caitlin J. Hardy, Assaf Tal, James S. Babb, Nissa N. Perry, Julie Walsh‐Messinger, Daniel Antonius, Dolores Malaspina, Oded Gonen · 2011 · Radiology
  27. Alterations of neurometabolism in the dorsolateral prefrontal cortex and thalamus in transition to psychosis patients change under treatment as usual – A two years follow-up 1H/31P-MR-spectroscopy study
    Stefan Smesny, Diana Berberich, Alexander Gussew, Nils Schönfeld, Kerstin Langbein, Mario Walther, Jürgen Rainer Reichenbach · 2021 · Schizophrenia Research
  28. Variability and Magnitude of Brain Glutamate Levels in Schizophrenia: A Meta and Mega-Analysis
    Kate Merritt, Robert Ali McCutcheon, André Aleman, Sarah A. Ashley, Katherine Beck, Wolfgang Block, Oswald Bloemen, Faith Borgan, Christina Boules, Juan Bustillo et al. · 2024 · Biological Psychiatry
  29. Hippocampal and thalamic neuronal metabolism in a putative rat model of schizophrenia.
    Guolin Ma, Tianbin Song, Min Chen, Yuan Fu, Yong Ji Xu, Ensen Ma, Wu Wang, Jiang Du, Mingxiong Huang · 2013 · PubMed Central
  30. 1H-magnetic resonance spectroscopy in first episode and chronic schizophrenia patients
    Duygu Kırtaş, Rukiye Filiz KARADAĞ, Melike Ceyhan Balcı Şengül, Yılmaz Kıroğlu · 2016 · TURKISH JOURNAL OF MEDICAL SCIENCES
  31. Current perspectives on the recognition and management of treatment-resistant schizophrenia: challenges and opportunities
    Myrto T. Samara, Georgios A. Alevizopoulos, Vasilis P. Bozikas, Ioannis Chatzimanolis, Dimitris G. Dikeos, Theodoros Mougiakos, Anastasia Nikolaou, Dimitrios Sakellariou, Charalampos Touloumis, Christos Tsopelas et al. · 2025 · Expert Review of Neurotherapeutics
  32. N-ACETYLCYSTEINE NORMALIZES NEUROCHEMICAL CHANGES IN THE GLUTATHIONE-DEFICIENT SCHIZOPHRENIA MOUSE MODEL DURING DEVELOPMENT
    Anita Kulak · 2012 · Schizophrenia Research
  33. From synaptic activity to human in vivo quantification of neurotransmitter dynamics: a neural modelling approach
    Caroline Lea‐Carnall, Wael El‐Deredy, Stephen R. Williams, Charlotte Jane Stagg, Nelson J. Trujillo‐Barreto · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  34. Elevated brain glutamine levels in adults with autism spectrum disorder: A 7T MRS study
    Manabu Kubota, Yujiro Yoshihara, Teruhisa Uwatoko, Rin Shoji, Jamie Near, Masoumeh Dehghani, Yuta Y. Aoki, Shin-ichi Urayama, Tomohisa Okada, Toshiya Murai · 2025 · Molecular Psychiatry
  35. Reward disturbances in antipsychotic-naïve patients with first-episode psychosis and their association to glutamate levels
    Karen Tangmose, Egill Rostrup, Kirsten Borup Bojesen, Anne Korning Sigvard, Kasper Jessen, Louise Baruël Johansen, Birte Yding Glenthoj, Mette Ødegaard Nielsen · 2021 · Psychological Medicine
  36. Neurotoxic Vulnerability Underlying Schizophrenia Spectrum Disorders
    Trevor Archer, Ulla Karilampi, Serafino Ricci, Max Rapp‐Ricciardi · 2014 · Springer eBooks
  37. Spectral editing in proton magnetic resonance spectroscopy. Determination of GABA level in the brains of humans with ultra-high risk for schizophrenia
    Petr E. Menshchikov, Н. А. Семенова, Maxim V. Ublinskiy, Tolibdzhon A. Akhadov, R A Keshishian, И. С. Лебедева, Maria A. Omelchenko, В. Г. Каледа, Sergei D. Varfolomeev · 2015 · Russian Chemical Bulletin
  38. The quest for biomarkers in Schizophrenia: from neuroimaging to machine learning
    M. Bajouco, David Mota, Manuel Coroa, Salomé Caldeira, Vítor Santos, Nuno Gonçalo Gomes Fernandes Madeira · 2017 · International Journal of Clinical Neurosciences and Mental Health
  39. Association of SLC6A3 variants with treatment-resistant schizophrenia: a genetic association study of dopamine-related genes in schizophrenia
    Masanobu Kogure, Nobuhisa Kanahara, Atsuhiro Miyazawa, Yuki Shiko, Ikuo Otsuka, Koichi Matsuyama, Masayuki Takase, Makoto Kimura, Hiroshi Kimura, Kiyomitsu Ota et al. · 2024 · Frontiers in Psychiatry
  40. Aging in Schizophrenia: Perspectives on Molecular Mechanisms and a Mini-review
    Akila Weerasekera, Öngür Dost, Du Fei · 2025 · Schizophrenia Bulletin
  41. Intranasal Insulin Increases Brain Glutathione and Enhances Antioxidant Capacity in Healthy Participants but Not in Those With Early Psychotic Disorders
    Virginie‐Anne Chouinard, Wirya Feizi, Xi Chen, Boyu Ren, Kathryn E. Lewandowski, Jacey Anderson, Steven Prete, Emma Tusuzian, Kyle Cuklanz, Shuqin Zhou et al. · 2024 · Biological Psychiatry Cognitive Neuroscience and Neuroimaging
  42. Proton magnetic resonance spectroscopy changes in a longitudinal schizophrenia study: a pilot study in eleven patients
    Beata Galińska-Skok, Agata Szulc, Aleksandra Małus, Beata Konarzewska, Urszula Cwalina, Eugeniusz Tarasów, Napoleon Waszkiewicz · 2019 · Neuropsychiatric Disease and Treatment
  43. Regional brain network and behavioral alterations in EGR3 gene transfected rat model of schizophrenia
    Wenwen Gao, Guangfei Li, Xiaowei Han, Zeyu Song, Shuai Zhao, Feiyi Sun, Hong Ma, Ailing Cui, Yige Wang, Xiuxiu Liu et al. · 2021 · Brain Imaging and Behavior
  44. Changes in glutamate levels in anterior cingulate cortex following 16 weeks of antipsychotic treatment in antipsychotic-naïve first-episode psychosis patients
    Jose Omar Maximo, Eric A. Nelson, Nina Vanessa Kraguljac, Rita Patton, Adil Bashir, Adrienne Carol Lahti · 2025 · Psychological Medicine
  45. Neurophysiology of Cognitive Dysfunction in Schizophrenia
    Corinna Haenschel, David E.J. Linden · 2011 · Springer eBooks
  46. Glutamate, Glutamatergic Drugs and Schizophrenia
    Carolina Muguruza, Luis Felipe Callado · 2022 · Springer eBooks
  47. The use of adjuvant L-arginine in schizophrenia: A behavioural and neurochemical analysis
    Mary-Anne B. MacKay · 2016 · ERA: Education and Research Archive (University of Alberta)
  48. Glutamatergic neurotransmission in schizophrenia: a systematic review protocol of 1H-MRS studies throughout phenotypic stages of schizophrenia
    Jamie J Lopes, Brian Dean, Sean P. Carruthers, Susan Lee Rossell · 2020
  49. Glutamate and bioenergetic abnormalities in the emergence and evolution of schizophrenia
    Döst Öngür · 2013 · Dusunen Adam The Journal of Psychiatry and Neurological Sciences
  50. A 1H-MRS and Neurocognitive Analysis of Psychotic Symptoms in Stimulant Dependence
    Bonnie Lakusta · 2012 · ERA: Education and Research Archive (University of Alberta)
  51. Magnetresonanzverfahren
    Ralf G.M. Schlösser, Kathrin Koch, Stefan Smesny · 2011 · Springer eBooks
  52. Hippocampal subfield activity in schizophrenia: Effects of the disease course
    Elena I. Ivleva, Jayme M. Palka, Anastasia M. Bobilev, Yan Fang, Carolyn Sacco, Alexa Ciarolla, Sina Aslan, Peiying Liu, Hanzhang Lu, Carol A. Tamminga · 2025 · Schizophrenia Research
  53. Energetic dysregulations in psychotic disorders: Targets for new therapeutics
    Jacey Anderson, Kai‐Christian Sonntag, Thao Do Vy Le, Kaitlin Shannon, Chao Wang, Fei Du, Xi Chen, Donna L. McPhie, Döst Öngür, Bruce M. Cohen et al. · 2026 · FEBS Journal